Core Insights - The gene therapy (CGT) sector is experiencing a significant decline in venture capital investment, with deals dropping by approximately 61% from 2021 to 2025, and CGT-specific deals decreasing by 66% in the same timeframe [1][2] Industry Trends - Half of the CGT venture capital activity is concentrated in Series B funding, indicating a shift from platform validation to clinical studies, reflecting a broader trend in the pharmaceutical industry towards less risky targets like obesity drugs and antibody-drug conjugates (ADCs) [2] - The average value of CGT venture capital deals is currently around $60 million in 2025, which is notably lower compared to other modalities, highlighting a decrease in deal frequency and value [3] Market Dynamics - The peak activity for venture capital in the CGT sector occurred in 2021, but commercial challenges have led some companies to withdraw from the space despite the presence of approved CGT therapies in major markets like the US and Europe [4] - Companies such as Galapagos and Takeda have recently exited the cell therapy sector, indicating a shift in focus towards small molecules, biologics, and ADCs [5] Acquisition Strategies - There is ongoing interest from biopharma companies in CGT technologies, primarily through acquisitions rather than in-house development, with a focus on platforms and scalable manufacturing systems [6] - Eli Lilly has been notably active in the CGT space, investing $475 million in a licensing deal for ophthalmology gene therapy and acquiring Adverum Biotechnologies for over $260 million, along with a $1.3 billion investment in Rznomics for RNA-based gene therapies [6]

Core Viewpoint - The law firm Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws on behalf of investors in uniQure N.V. following significant stock price decline after FDA feedback on its gene therapy AMT-130 [1][4]. Group 1: Company Developments - On November 3, 2025, uniQure announced that the FDA indicated the data for its investigational gene therapy AMT-130 did not provide sufficient evidence to support its Biologics License Application (BLA) [2]. - uniQure believes the FDA no longer considers the Phase I/II study data adequate for BLA submission, leading to uncertainty regarding the timing of the BLA submission for AMT-130 [2]. Group 2: Market Reaction - Following the announcement, uniQure's stock price plummeted over 50%, dropping from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [3].

Core Insights - Solid Biosciences Inc. is presenting data on its proprietary capsid AAV-SLB101 and cardiac gene therapy pipeline at the Global CardioVascular Clinical Trialists Forum from December 8-10, 2025 [1][2] - The company aims to showcase the potential of its precision genetic approach to treat cardiac diseases, emphasizing the benefits of AAV-SLB101 [3][6] - Key personnel, including Dr. Gabriel Brooks and Dr. Nicolas Christoforou, will deliver presentations and participate in panel discussions at the forum [1][5][6] Company Overview - Solid Biosciences focuses on developing precision genetic medicines targeting rare neuromuscular and cardiac diseases, with a diverse pipeline including candidates for Duchenne muscular dystrophy and catecholaminergic polymorphic ventricular tachycardia [8] - The company is committed to advancing innovative genetic regulators and technologies to enhance gene therapy delivery across the industry [8] - Founded by individuals affected by Duchenne, Solid's mission is to improve the lives of patients with rare diseases [8]

Core Insights - Congressman Tim Moore has made significant stock purchases in Hyster-Yale Inc, a small cap lift truck company, amid notable market activity and scrutiny [1][4][6] Group 1: Stock Transactions - Moore disclosed purchases of Hyster-Yale shares totaling between $145,000 and $350,000, with the company's market capitalization around $620 million [2] - His previous transactions included buying $80,000 to $200,000 in shares in October and selling between $100,000 and $250,000 later in the month [4] - Recent purchases did not include any sales, but the stock price surged from $28.12 to $35.03 following the news of his transactions [5] Group 2: Company Background - Hyster-Yale has a history of signing government contracts, which raises questions about the implications of Moore's trades [5] - Moore also made a notable purchase of Genprex shares, a clinical stage gene therapy company with a market capitalization of less than $10 million, indicating a trend towards investing in smaller companies [6] Group 3: Market Reaction - The stock of Hyster-Yale experienced a significant increase in value following the announcement of Moore's purchases, highlighting the potential impact of political figures on stock prices [5]

Table of Contents As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333-291722 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 GENPREX, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 90-0772347 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identifi ...

Group 1 - uniQure N.V. (NASDAQ:QURE) is considered one of the most oversold biotech stocks, with a reaffirmed Market Perform rating from William Blair [1] - The company is facing regulatory challenges regarding its AMT-130 therapy, as the FDA no longer deems the results from Phase 1/2 studies sufficient for a Biologics License Application (BLA) [2] - uniQure anticipates receiving final minutes from the pre-BLA meeting within 30 days and plans to engage proactively with the FDA for accelerated approval of AMT-130 [3] Group 2 - The strong clinical results released last month and early interest from patients and physicians for the Huntington's disease medication may lead to pressure on regulators for a quicker BLA submission [1]

Core Insights - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases and aims to present significant progress at the upcoming NobleCon21 conference [1][2][4] - The company is targeting three Biologics License Applications (BLAs) within three years and plans to discuss near-term catalysts for 2026 during the conference [2][4] Company Overview - Ocugen's modifier gene therapy platform addresses complex diseases caused by imbalances in multiple gene networks, offering a gene-agnostic approach [4] - Current development programs include treatments for inherited retinal diseases and blindness diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy [4] Conference Details - Dr. Shankar Musunuri will present on December 3, 2025, at 1 p.m. ET, with a focus on the company's scientific platform and clinical development strategy [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3]

Core Insights - uniQure N.V. is viewed positively by Wall Street despite regulatory challenges from the FDA regarding its gene therapy AMT-130 [1][3] - The company presented significant results from a three-year study showing a reduction in Huntington's disease progression [2] - The FDA has expressed concerns about the adequacy of data from early Phase I/II studies for AMT-130, leading to uncertainty about the pre-Biologics License Application timeline [3] Analyst Ratings - Wells Fargo analyst Yanan Zhu reiterated a Buy rating on uniQure N.V. but lowered the price target from $80 to $60 [1] - TD Cowen analyst Joseph Thome maintained a Buy rating without disclosing a price target, expressing confidence in the company's data and potential [1][4] Company Background - uniQure N.V. is a Netherlands-based biotechnology company focused on developing gene therapies aimed at curing severe genetic diseases with a single administration [4]

Core Points - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Waskyra™, an ex-vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency [1][5] - Fondazione Telethon is the first non-profit organization to successfully navigate the entire process from laboratory research to regulatory approval, collaborating with industry partners to bring gene therapies from discovery to patients [2][10] - Waskyra™ represents a significant scientific and clinical achievement, providing new hope for patients affected by WAS [3][4] Company Information - Fondazione Telethon has been supporting impactful scientific research for over 35 years, focusing on developing innovative treatment methods for rare and complex genetic diseases [10] - The therapy was developed at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, which is recognized as a center of excellence for gene therapy [3][4] Therapy Details - Waskyra™ involves a one-time administration of autologous CD34+ hematopoietic stem and progenitor cells that have been transduced with a lentiviral vector encoding the WAS gene [8] - The therapy has shown to reduce the frequency of severe and moderate bleeding as well as severe infections in patients with WAS compared to the period before treatment [9] - The current treatment options for WAS are limited, with hematopoietic stem cell transplantation being the only potentially curative option, which is not always available due to donor compatibility issues [7]

Core Insights - Benitec Biopharma Inc. has received Fast Track Designation from the FDA for its gene therapy BB-301, which shows promise in treating Oculopharyngeal Muscular Dystrophy (OPMD) with a 100% responder rate in initial clinical trials [1][4][11] - The company successfully raised approximately $100 million through a public offering to support the advancement of BB-301 and related regulatory activities [1][5][6] - The first patient in Cohort 2 of the BB-301 trial was treated successfully, indicating progress in the clinical development of the therapy [1][4] Clinical Development - The Phase 1b/2a trial of BB-301 demonstrated a 100% responder rate in Cohort 1, with all six patients meeting the statistical criteria for response [1][4] - Significant improvements in swallowing function were observed in patients following treatment with BB-301 [4] - The FDA's Fast Track Designation aims to expedite the development and review process for BB-301, which targets dysphagia associated with OPMD [1][4][11] Financial Performance - For the first fiscal quarter ended September 30, 2025, total expenses were $9.8 million, up from $5.8 million in the same quarter of the previous year [6][7] - Research and development expenses were $3.4 million, slightly down from $3.6 million year-over-year, while general and administrative expenses increased significantly to $6.4 million from $2.2 million [6][7] - The net loss attributable to shareholders for the quarter was $9.0 million, or $(0.22) per share, compared to a net loss of $5.1 million, or $(0.18) per share, in the prior year [7][9] Corporate Updates - Benitec appointed Sharon Mates, Ph.D., to its Board of Directors, enhancing its leadership team [3] - The company hosted a webcast to discuss the positive interim clinical study results, indicating transparency and engagement with stakeholders [4] Capital Raise - The company completed an underwritten public offering of 5,930,000 shares at $13.50 per share, along with a direct offering of 1,481,481 shares to a long-term investor [5] - The net proceeds from this financing are intended to support the continued development of BB-301 and other corporate purposes [5]